

# Simon Pernot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9374395/publications.pdf>

Version: 2024-02-01

43  
papers

2,756  
citations

361296  
20  
h-index

254106  
43  
g-index

45  
all docs

45  
docs citations

45  
times ranked

5206  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. <i>British Journal of Cancer</i> , 2022, 126, 1394-1400.	2.9	5
2	Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. <i>Digestive and Liver Disease</i> , 2022, 54, 324-330.	0.4	5
3	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101681.	0.7	4
4	Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101603.	0.7	12
5	Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients. <i>Cancers</i> , 2021, 13, 5562.	1.7	6
6	Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. <i>Statistical Methods in Medical Research</i> , 2020, 29, 541-567.	0.7	8
7	Withholding the Introduction of Anti-epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). <i>Oncologist</i> , 2020, 25, e266-e275.	1.9	3
8	Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 295-301.	0.7	13
9	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. <i>Gastric Cancer</i> , 2020, 23, 73-81.	2.7	75
10	Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2020, 19, 39-47.e5.	1.0	9
11	Plasma clearance of <i>RAS</i> mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 1185-1189.	2.3	26
12	Factors associated with anal cancer screening uptake in men who have sex with men living with HIV: a cross-sectional study. <i>European Journal of Cancer Prevention</i> , 2020, 29, 1-6.	0.6	5
13	Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. <i>British Journal of Cancer</i> , 2020, 123, 518-524.	2.9	16
14	Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. <i>Drugs</i> , 2020, 80, 401-415.	4.9	42
15	Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987866.	1.4	39
16	Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study. <i>European Journal of Cancer</i> , 2019, 119, 35-43.	1.3	24
17	Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: A cross-sectional study. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1195-1203.	0.5	6
18	HPV-circulating tumoural DNA by droplet-based digital polymerase chain reaction, a new molecular tool for early detection of HPV metastatic anal cancer? A case report. <i>European Journal of Cancer</i> , 2019, 112, 34-37.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Immunotherapy in advanced gastric cancer, is it the future?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 25-32.	2.0	97
20	Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey. <i>Oncologist</i> , 2019, 24, e1351-e1359.	1.9	42
21	5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 255-260.	0.7	7
22	FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. <i>European Journal of Cancer</i> , 2018, 104, 108-116.	1.3	17
23	Colorectal Cancer: Why Does Side Matter?. <i>Drugs</i> , 2018, 78, 789-798.	4.9	41
24	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1094-1106.	5.1	108
25	Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2018, 29, iv126-iv142.	0.6	83
26	Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men. <i>British Journal of Cancer</i> , 2018, 119, 381-386.	2.9	34
27	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , 2018, 119, 424-428.	2.9	22
28	What treatment in 2017 for inoperable pancreatic cancers?. <i>Annals of Oncology</i> , 2017, 28, 1473-1483.	0.6	30
29	Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. <i>European Journal of Cancer</i> , 2017, 79, 15-22.	1.3	42
30	Percutaneous radiofrequency ablation of lung metastases from colorectal carcinoma under C-arm cone beam CT guidance. <i>Diagnostic and Interventional Imaging</i> , 2017, 98, 793-799.	1.8	7
31	HIV1-positive men who have sex with men (HIV1-MSM) knowledge and attitudes towards anal cancer screening: A cross-sectional study. <i>Annals of Oncology</i> , 2016, 27, vi462.	0.6	1
32	Checkpoint inhibitors and gastrointestinal immune-related adverse events. <i>Current Opinion in Oncology</i> , 2016, 28, 264-268.	1.1	35
33	Reply to the comment on "Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort". <i>British Journal of Cancer</i> , 2016, 114, e9-e9.	2.9	3
34	Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. <i>World Journal of Gastroenterology</i> , 2015, 21, 11428.	1.4	226
35	VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. <i>Journal of Experimental Medicine</i> , 2015, 212, 139-148.	4.2	836
36	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. <i>British Journal of Cancer</i> , 2015, 113, 989-995.	2.9	151

#	ARTICLE	IF	CITATIONS
37	Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e73-e77.	0.7	13
38	Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. <i>Annals of Oncology</i> , 2015, 26, 149-156.	0.6	98
39	Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfinox: Results of an AGEO multicenter prospective cohort.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4123-4123.	0.8	6
40	Docetaxel, 5FU, oxaliplatin (TEFOX) in 1st line treatment of signet ring cell and/or poorly differentiated gastric adenocarcinoma: a retrospective study of AGEO.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15048-e15048.	0.8	6
41	Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. <i>Gastric Cancer</i> , 2014, 17, 341-347.	2.7	18
42	VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer. <i>Cancer Research</i> , 2013, 73, 539-549.	0.4	528
43	Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1